EXOZ

eXoZymes, Inc. is a biotechnology company within the healthcare sector, with a market capitalization of $89.40 million and 31 employees. The company's financial health is marked by significant losses, with net income and EBITDA both totaling negative figures: -$8,339,672 and -$8,722,368, respectively. The gross margin, operating margin, and profit margin are all at 0.0%. Returns on equity and assets are also negative, standing at -940.7% and -99.8%, respectively. The debt to equity ratio is 24.56, while the company has $5.10 million in cash and $1.32 million in debt. The company's valuation context includes a price to book ratio of 16.63, which is the only available valuation metric. Growth rates are not provided, and dividend information is also unavailable.